Biosimilar Products We Support Through Global Supply Networks
Oddway International supports sourcing and supply coordination for a broad range of biosimilar medicines used across oncology, immunology, rheumatology, ophthalmology, haematology, endocrinology, respiratory medicine, and rare disease management. Product availability may vary depending on market authorisations, manufacturer supply status, and destination-country regulations.
| Therapeutic Area | Biosimilar Products |
|---|
| Oncology Biosimilars | Aflibercept Biosimilar, Bevacizumab Biosimilar, Cetuximab Biosimilar, Rituximab Biosimilar, Trastuzumab Biosimilar, Obinutuzumab Biosimilar, Alemtuzumab Biosimilar, Pembrolizumab Biosimilar, Nivolumab Biosimilar, Atezolizumab Biosimilar, Emicizumab Biosimilar, Bortezomib Biosimilar |
| Autoimmune & Inflammatory Disease Biosimilars | Adalimumab Biosimilar, Infliximab Biosimilar, Etanercept Biosimilar, Golimumab Biosimilar, Ustekinumab Biosimilar, Tocilizumab Biosimilar, Guselkumab Biosimilar, Ixekizumab Biosimilar, Abatacept Biosimilar, Natalizumab Biosimilar, Ocrelizumab Biosimilar, Dupilumab Biosimilar, Benralizumab Biosimilar, Mepolizumab Biosimilar, Omalizumab Biosimilar |
| Ophthalmology Biosimilars | Ranibizumab Biosimilar |
| Rare Disease & Specialty Biosimilars | Eculizumab Biosimilar, Ravulizumab Biosimilar, Palivizumab Biosimilar, Evolocumab Biosimilar |
Global Biosimilar Supply Support
As a biosimilar drugs supplier, Oddway International supports licensed distributors, hospitals, healthcare institutions, procurement agencies, and authorised importers seeking access to high-quality biosimilar medicines from established manufacturers. Our team assists with documentation, batch traceability, procurement support, and supply-chain coordination to help ensure a reliable sourcing experience.
We support enquiries related to aflibercept biosimilar, infliximab biosimilar, adalimumab biosimilar, rituximab biosimilar, ustekinumab biosimilar, tocilizumab biosimilar, bevacizumab biosimilar, denosumab biosimilar, eculizumab biosimilar, omalizumab biosimilar, filgrastim biosimilar, cetuximab biosimilar, teriparatide biosimilar, alemtuzumab biosimilar, benralizumab biosimilar, ranibizumab biosimilar, pegfilgrastim biosimilar, pembrolizumab biosimilar, trastuzumab biosimilar, tirzepatide biosimilar, semaglutide biosimilar, and many other specialty biologic alternatives.
Disclaimer: Product availability, regulatory status, and supply eligibility vary by market. All products are supplied subject to applicable laws, local regulations, and manufacturer authorisations.